micro-crystalline cellulose
Sponsors
Arctic Therapeutics ehf., Washington University School of Medicine, University of Glasgow, Usona Institute, Nuritas Ltd
Conditions
Alzheimer's DiseaseCognitive AbilitiesCortisolExerciseGastroenteritisHealthy ParticipantsInflammationOxidative Stress
Phase 1
Phase 2
Impact of Emergency Department Probiotic (LGG) Treatment of Pediatric Gastroenteritis
CompletedNCT01773967
Start: 2014-07-31End: 2018-08-31Updated: 2019-09-06
A phase 2a multi-site, randomized, double-blind, dose escalated, placebo-controlled biomarker study to determine the safety, tolerability and biomarker-based efficacy of NPI-001 (AT-001) in subjects with MCI (Mild Cognitive Impairment) or mild dementia due to Alzheimer’s disease (AD) aged 50 to 85 years
RecruitingCTIS2024-519497-39-00
Start: 2025-10-03Target: 30Updated: 2025-09-22